Who MITIGO™ Helps

Over 100 million Americans suffer from chronic pain. MITIGO Morphine Sulfate Injection can help.

Chronic pain is more common than you might think. With a rate of 13-51%, it’s more prevalent than diabetes, cancer and heart disease combined, and affects more than 100 million Americans. The quality of life scores for those with chronic pain are often lower than those with progressive neurological disorders, such as Parkinson’s disease. IOM estimates that the cost of treating pain is $635 Billion annually.

The treatment and management of chronic pain can be cumbersome and confusing. But it doesn’t have to be. That’s where MITIGO can help.

MITIGO, a USP and preservative-free injectable solution, is the only FDA-approved morphine sulfate injection for intrathecal or epidural infusion pain management. The drug is administered through a continuous microinfusion device and goes directly to the pain site.

As we’ve witnessed the rise of the opioid crisis, a modified treatment approach, like intrathecal, has been recognized as being safer and more effective than oral opioids.

medical staff with a patient in a hospital setting

Benefits of Targeted Drug Delivery Therapy

  • May increase pain relief for patients who have not received adequate relief with conventional therapies
  • May reduce the risk of experiencing adverse effects from oral opioids such as nausea, vomiting, sedation, and constipation
  • May decrease or eliminate the use of oral analgesics
  • Increases ability to perform activities of daily living
  • Patient control of medication within physician-set limits 11
  • May be effective for patients who do not experience relief from spinal cord stimulation therapy

MITIGO’s intrathecal, targeted drug delivery helps patients avoid risk of abuse, addiction, and overdose.

Other benefits of this intrathecal medication include:

  • More effective and less dangerous than long-term opioids use
  • Less invasive than dorsal column stimulation or corrective surgery
  • Much higher drug concentration at the right site
  • Controlled treatment and morphine sulfate dosage, reducing the risk of misuse or overuse
  • Less medication, less blood level of medication, less or no side effects
  • Better pain control, less toxicity, and reduced mortality
  • Less dose escalation over time
  • Much higher drug concentration at target receptor sites in the spinal cord and much lower blood levels
  • Uses a fraction of the oral dose (1 to 100/300)
  • May result in fewer or more tolerable side effects, such as vomiting and fatigue
  • Better pain relief
  • Cheaper than CMM over time and decreases healthcare utilization

Contact Us

MITIGO helps patients improve their quality of life while managing their pain. Contact us to see if your patients are eligible for a trial and to get started with targeted drug delivery.

Contact Us

Important Risk Information
INDICATIONS AND USAGE

MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

IMPORTANT RISK INFORMATION

WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENING RESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

See full prescribing information for complete boxed warning.

  • Single-dose neuraxial administration may result in acute or delayed respiratory depression up to 24 hours. Because of the risk of severe adverse reactions when MITIGO is administered by the epidural or intrathecal route of administration, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose.
  • Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Patients must be observed in a fully equipped and staffed environment for at least 24 hours after each test dose and, as indicated, for the first several days after surgery.
  • MITIGO exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions.
  • Prolonged use of MITIGO during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
  • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
CONTRAINDICATIONS
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting in absence of resuscitative equipment
  • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity or intolerance to morphine

Neuraxial administration of MITIGO is contraindicated in patients with:

  • Infection at the injection microinfusion site
  • Concomitant anticoagulant therapy
  • Uncontrolled bleeding diathesis
  • The presence of any other concomitant therapy or medical condition which would render epidural or intrathecal administration of medication especially hazardous.
WARNINGS AND PRECAUTIONS
  • Risk of Inflammatory Masses: Monitor patients receiving continuous infusion of MITIGO via indwelling intrathecal catheter for new signs or symptoms of neurologic impairment.
  • Risk of Tolerance and Myoclonic Activity: Monitor patients for unusual acceleration of neuraxial morphine, which may cause myoclonic-like spasm of lower extremities. Detoxification may be required.
  • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.
  • Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
  • Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of MITIGO in patients with circulatory shock.
  • Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of MITIGO in patients with impaired consciousness or coma.
ADVERSE REACTIONS

Most serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: May cause fetal harm.
  • Hepatic and Renal Impairment: May affect the metabolism and excretion of MITIGO.

To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional Important Risk Information, including boxed warning, see enclosed Full Prescribing Information.

INDICATIONS AND USAGE

MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

IMPORTANT RISK INFORMATION

WARNING: RISKS WITH NEURAXIAL ADMINISTRATION; LIFE-THREATENING RESPIRATORY DEPRESSION; RISK OF ADDICTION, ABUSE, AND MISUSE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

See full prescribing information for complete boxed warning.

  • Single-dose neuraxial administration may result in acute or delayed respiratory depression up to 24 hours. Because of the risk of severe adverse reactions when MITIGO is administered by the epidural or intrathecal route of administration, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose.
  • Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Patients must be observed in a fully equipped and staffed environment for at least 24 hours after each test dose and, as indicated, for the first several days after surgery.
  • MITIGO exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions.
  • Prolonged use of MITIGO during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
  • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
CONTRAINDICATIONS
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting in absence of resuscitative equipment
  • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity or intolerance to morphine

Neuraxial administration of MITIGO is contraindicated in patients with:

  • Infection at the injection microinfusion site
  • Concomitant anticoagulant therapy
  • Uncontrolled bleeding diathesis
  • The presence of any other concomitant therapy or medical condition which would render epidural or intrathecal administration of medication especially hazardous.
WARNINGS AND PRECAUTIONS
  • Risk of Inflammatory Masses: Monitor patients receiving continuous infusion of MITIGO via indwelling intrathecal catheter for new signs or symptoms of neurologic impairment.
  • Risk of Tolerance and Myoclonic Activity: Monitor patients for unusual acceleration of neuraxial morphine, which may cause myoclonic-like spasm of lower extremities. Detoxification may be required.
  • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.
  • Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
  • Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of MITIGO in patients with circulatory shock.
  • Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of MITIGO in patients with impaired consciousness or coma.
ADVERSE REACTIONS

Most serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: May cause fetal harm.
  • Hepatic and Renal Impairment: May affect the metabolism and excretion of MITIGO.

To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional Important Risk Information, including boxed warning, see enclosed Full Prescribing Information.